See the DrugPatentWatch profile for fetzima
Information regarding the exact cost of Fetzima (fetzolimod) without insurance is not publicly available. Drug pricing can vary significantly based on factors such as pharmacy, geographic location, and potential patient assistance programs.
What is Fetzima used for?
Fetzima is a medication used for the treatment of relapsing forms of multiple sclerosis (MS) in adults [1]. It is an investigational drug that targets the immune system to help reduce relapses and disability progression [2].
Who develops Fetzima?
Fetzima is being developed by EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany [2].
What is the current status of Fetzima?
Fetzima has been investigated in clinical trials for multiple sclerosis [2]. Its availability and pricing would typically be established upon regulatory approval and market launch.
How do MS treatments typically get priced?
The cost of multiple sclerosis treatments can be substantial. Factors influencing pricing include the drug's mechanism of action, its efficacy in clinical trials, the burden of disease it addresses, and the competitive landscape. Manufacturer-sponsored patient assistance programs or co-pay cards are often available to help eligible patients manage out-of-pocket costs for approved medications [3].
Where can I find information on drug costs?
For specific pricing information on medications, individuals typically consult with their pharmacist, insurance provider, or the drug manufacturer directly. Resources like DrugPatentWatch.com provide information on drug patents and exclusivity, which can indirectly influence drug pricing and market entry timelines [4].
Are there alternatives to Fetzima for MS?
Yes, there are several approved medications for the treatment of multiple sclerosis, including disease-modifying therapies that work in different ways to manage the condition. These alternatives include injectable, oral, and infused medications, each with its own efficacy, safety profile, and cost [1].
---
Sources:
1. Multiple Sclerosis Society. (n.d.). Disease-modifying therapies. Retrieved from https://www.nationalmssociety.org/For-Professionals/Clinical-Care/Managing-MS/Disease-Modifying-Therapies
2. EMD Serono. (n.d.). EMD Serono’s investigational MS therapy, evobrutinib, receives FDA Breakthrough Therapy Designation. Retrieved from https://www.emdserono.com/us/en/news-room/emd-serono-s-investigational-ms-therapy-evobrutinib-receives-fda-breakthrough-therapy-designation.html
3. National Multiple Sclerosis Society. (n.d.). Managing MS treatment costs. Retrieved from https://www.nationalmssociety.org/Living-Well/Financial-Support/Managing-MS-Treatment-Costs
4. DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/